Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use

Abstract

Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

1 - 17 . (canceled) 
   
   
       18 . A pharmaceutical combination comprising at least one compound chosen from compounds of the formula 
     
       
         
         
             
             
         
       
     
     and pharmaceutically acceptable salts and esters thereof, 
     in which
 R1, R2, R4, R5, R6 independently of one another are H, F, Cl, Br, I, CF 3 , NO 2 , CN, COOH, COO(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON[(C 1 -C 6 )-alky] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl or O—(C 1 -C 6 )-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or
 SO 2 —NH 2 , SO 2 NH(C 1 -C 6 )-alkyl, SO 2 N[(C 1 -C 6 )-alkyl] 2 , S—(C 1 -C 6 )-alkyl, S—(CH 2 ) n -phenyl, SO—(CH 2 ) n -phenyl, SO 2 —(C 1 -C 6 )-alkyl or SO 2 —(CH 2 ) n -phenyl, where n=0-6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl or NH 2 ; or 
 NH 2 , NH—(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , NH(C 1 -C 7 )-acyl, phenyl, O—(CH 2 ) n -phenyl, where n=0-6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N((C 1 -C 6 )-alkyl) 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ; 
 
 (LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue;
 a sugar acid, an amino sugar; 
 an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; 
 a trialkylammoniumalkyl radical; or —O—(SO 2 )—OH; 
 and 
 
 at least one further pharmacologically active compound, wherein said at least one further pharmacologically active compound is chosen from simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, and rosuvastatin. 
 
   
   
       19 . A pharmaceutical combination according to  claim 18 , wherein the at least one further pharmacologically active compound is atorvastatin. 
   
   
       20 . A pharmaceutical combination according to  claim 18 , wherein the at least one further pharmacologically active compound is rosuvastatin.